Ashish Saxena, MD, PhD, assistant attending at New York-Presbyterian Hospital and assistant professor of medicine at Weill Cornell Medical College, reviews first-line therapies in non-small cell lung cancer. Dr. Saxena explains that, while no comparative research is available for brigatinib and alectinib, brigatinib covers certain resistance mutations and may result in longer progression-free survival. For second-line therapies, Dr. Saxena recommends chemotherapy but is encouraged by the prospect of novel drugs and treatment regimens.

Learn more by clicking here.